When: Close >$58.60 (200 SMA) on volume ≥7M with MACD histogram narrowing toward zero AND RSI >45

Then: Scale to 4.5% with stop at $58.00

When: Close <$55.86 with volume ≥10M

Then: Trim to 85-90% of benchmark weight; downside target $53.40-$54.00

When: MDLZ underperforms SPY by -1.0% over any 5-session rolling window (tested intra-week)

Then: AUTOMATICALLY trim 5% into strength

When: Pullback to $53.40-$54.00 with RSI <30 and capitulation volume

Then: Defensive add with stop at $51.00

HOLD at current weight (three to five percent), collect dividend as paid-to-wait cushion, require confirmation before adding. Do not initiate new capital until Q2 2026 earnings confirm recovery and price closes above fifty-nine fifty with MACD narrowing.

• MACD at minus zero point nine one with histogram at minus zero point two six and expanding (fresh bearish momentum, not reversal)
• RSI at thirty-seven, still below fifty neutral level, no real reversal confirmation
• 200 SMA has flipped to overhead resistance at fifty-eight sixty with price below it
• Q1 2026 gross margin twenty-seven point eight percent, only one hundred seventy basis point improvement over Q1 2025's twenty-six point one percent
• Gross margin remains one thousand and twenty basis points below thirty-eight percent historical norm
• Zero quarters have printed above thirty percent gross margin to confirm recovery
• MDLZ returned four point eight seven billion dollars to shareholders in 2025 and stock still declined from early 2025 highs
• Three point four nine percent dividend yield compresses when ten-year pays five percent plus
• Low beta of zero point three nine measures equity market sensitivity, not interest rate sensitivity
• Defensive staples historically rerate downward when ten-year rises above four point five percent
• Ten-year at highest level since 2002 with biggest monthly gain since 2022
• No company-specific catalyst in the tape for seven trading days
• Conservative position sizing is three to five percent, not the aggressive five to seven percent
• Downside risk to fifty-five eighty-six if fifty-seven thirty-eight breaks

→ vs aggressive: Coiled spring framing misuses support concept - 200 SMA has flipped to overhead resistance per the technical report, cannot simultaneously be support and resistance

→ vs aggressive: RSI bounce to thirty-seven is below fifty neutral level, not the fifty reclaim required to confirm real reversal - data mining for desired narrative

→ vs aggressive: Recovery thesis already printing is inconsistent with analyst's own HOLD thesis citing Q2 2026 as binary earnings print requiring confirmation

→ vs aggressive: Capital return floor argument conflates income statement support with stock price floor - four point eight seven billion returned in 2025 did not prevent stock decline

→ vs aggressive: Low beta of zero point three nine insulates from equity market beta, not interest rate changes - category error relevant to current regime

→ vs aggressive: Position sizing up to five to seven percent is reckless when price below all moving averages, momentum expanding bearish, macro hostile, and no catalyst

→ vs aggressive: Coiled ATR expands and frequently comes with gap moves - sizing up increases gap-down risk through fifty-seven thirty-eight to fifty-five eighty-six

HOLD with tactical triggers: base 3-5% position; add up to 5% if close above 59.50 with MACD histogram narrowing toward zero and RSI reclaiming 45; trim to 2-3% if close below 57.38; add ahead of earnings if close above 61.38 (50 SMA) on volume

• ATR compression indicates volatility contraction, not direction of next expansion
• Price at 57.38 lower Bollinger Band; one bad session from breaking below to 55.86 stop level
• Risk-reward is roughly 1:1 on stop-out level, not asymmetric as aggressive analyst claims
• Q1 2026 gross margin of 27.8% versus 26.1% prior year is 170 basis point improvement, but historical norm is ~38%, still 1,020 basis points below
• Capital return of 4.87 billion in 2025 provides structural bid that most large caps lack, not a price floor
• 3.49% dividend yield compounds meaningfully over 12-18 month hold
• Holding at 3-5% waiting for Q2 2026 earnings has opportunity cost; if recovery prints and stock reaches 62-64, holder gives up 6-10% upside
• Q2 gross margin of 28.5% versus 30% expected creates ambiguity, not clear trigger for action
• 3.49% yield not compelling when 10-year at multi-decade highs; defensive staples need falling rates or recession scare to rally
• Beta of 0.39 is market sensitivity, not rate sensitivity; does not insulate from hawkish rate environment
• Conservative analyst's waiting-for-confirmation framing treats soft threshold as hard one
• Recommended position sizing: base 3-5%, tactical add up to 5% on close above 59.50 with favorable MACD/RSI
• Hard trim trigger: close below 57.38 reduces position to 2-3%
• Technical contingency: close above 61.38 (50 SMA) on volume signals regime change to add ahead of earnings

→ vs aggressive: Coiled spring narrative is a classic trap; ATR compression indicates direction is unknown, not imminent expansion. Risk-reward is roughly 1:1 on stop-out level (55.86), calling that asymmetric is wrong; it is a coin flip with a thesis attached.

→ vs aggressive: Beta of 0.39 insulates MDLZ is incorrect; beta measures market sensitivity, not rate sensitivity, and the hawkish-without-recession regime is genuinely hostile to this trade.

→ vs conservative: Capital return as not a price floor is technically correct but dismissive; 4.87 billion in returns and 3.49% dividend provide a structural bid that most large caps lack, not just noise.

→ vs conservative: Holding at 3-5% and waiting for Q2 earnings ignores opportunity cost; if recovery prints and stock reaches 62-64, holder gives up 6-10% of upside while collecting dividends.

→ vs conservative: Q2 earnings framed as binary are not actually binary; a 28.5% gross margin print versus 30% expected creates ambiguity, not a clear trigger. The conservative analyst treats a soft threshold as a hard one.

→ vs conservative: Wait-for-confirmation discipline is too rigid when price action can give the answer first; if MDLZ closes above 61.38 (50 SMA) on volume, that is regime change worth acting on ahead of earnings.